文献速递肿瘤 PET/CT骨显像与常规 SPECT

MRI、[18F]FDG-PET/CT 与 [18F]FDG-PET/MRI 用于多发性骨髓瘤初始分期的比较:系统综述与 Meta 分析

Comparison of MRI, [ 18 F]FDG-PET/CT, and [ 18 F]FDG-PET/MRI for Initial Staging of Multiple Myeloma : A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2025-07-08

该系统综述与 Meta 分析比较 MRI、[18F]FDG-PET/CT 和 [18F]FDG-PET/MRI 在多发性骨髓瘤初始分期中检测局灶性骨病变和骨髓浸润的诊断性能。共纳入 20 项研究(2007 至 2025 年发表),以国际 MM 诊断标准为参考标准。13 项研究(n=742)比较 [18F]FDG-PET/CT 与 MRI 的患者水平敏感性,合并敏感性分别为 0.807(95%CI 0.74-0.86)与 0.914(95%CI 0.88-0.94)(Meta 回归 P<0.001)。

要点

  • [18F]FDG-PET/CT 合并敏感性 0.807(95%CI 0.74-0.86),MRI 为 0.914(95%CI 0.88-0.94)。
  • 83%(599/721)患者 [18F]FDG-PET/CT 与 MRI 结果一致,14%(101/721)为 PET/CT 阴性而 MRI 阳性(P<0.001)。
  • 4 项含 [18F]FDG-PET/MRI 的研究合并敏感性为 0.944(95%CI 0.88-0.98)。

核心结论

  • 该系统综述与比较性 Meta 分析显示,WB-MRI 在多发性骨髓瘤初始分期中的敏感性优于 [18F]FDG-PET/CT。
  • 作者认为未来的国际指南可能将 MRI 和 [18F]FDG-PET/MRI 置于 MM 患者分期的优先位置。

研究设计与样本

  • 系统综述与 Meta 分析,检索 PubMed、Embase 和 Cochrane 数据库。
  • 纳入在同一批患者中比较 MRI(WB-MRI 或脊柱/骨盆 MRI)、[18F]FDG-PET/CT 和/或 [18F]FDG-PET/MRI 用于 MM 初始分期的研究。
  • 共纳入 20 项研究(2007 至 2025 年发表),以国际 MM 诊断标准为参考标准。
  • 13 项研究(n=742)比较 [18F]FDG-PET/CT 与 MRI 的患者水平敏感性,4 项研究(n=224)比较 MRI 与 [18F]FDG-PET/MRI。
  • 使用 R(META-R 包)分析合并敏感性与影像模态间一致性,采用 QUADAS-C 工具评估异质性与偏倚。

主要发现

  • [18F]FDG-PET/CT 合并敏感性为 0.807(95%CI 0.74-0.86,存在显著异质性),MRI 为 0.914(95%CI 0.88-0.94)(Meta 回归分析 P<0.001)。
  • MRI 亚组合并敏感性:脊柱/骨盆 MRI 为 0.906,WB-MRI 为 0.920。
  • 83%(599/721)纳入患者 [18F]FDG-PET/CT 与 MRI 结果一致,14%(101/721)患者 [18F]FDG-PET/CT 阴性而 MRI 阳性(配对样本分析 P<0.001)。
  • 4 项含 [18F]FDG-PET/MRI 的研究合并敏感性为 0.944(95%CI 0.88-0.98)。

关键数值与推荐

  • [18F]FDG-PET/CT 合并敏感性 0.807(95%CI 0.74-0.86),MRI 合并敏感性 0.914(95%CI 0.88-0.94),Meta 回归分析 P<0.001。
  • 脊柱/骨盆 MRI 合并敏感性 0.906,WB-MRI 合并敏感性 0.920。
  • [18F]FDG-PET/MRI 合并敏感性 0.944(95%CI 0.88-0.98)。
  • 83%(599/721)患者两种技术结果一致,14%(101/721)患者 [18F]FDG-PET/CT 阴性而 MRI 阳性,配对样本分析 P<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • [18F]FDG-PET/CT 合并敏感性分析存在显著异质性。
  • 作者指出,MM 影像学中特异性的共识定义应在各研究间实现标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This systematic review and meta-analysis compared the diagnostic performance of MRI, [ 18 F]FDG-PET/CT, and [ 18 F]FDG-PET/MRI in detecting focal bone lesions and bone marrow infiltration in the initial staging of patients with multiple myeloma (MM) who underwent both MRI and [ 18 F]FDG-PET/CT or [ 18 F]FDG-PET/MRI studies. PATIENTS AND METHODS: A systematic literature search was conducted across PubMed, Embase, and Cochrane databases, including studies comparing the performance of MRI (WB-MRI or spine/pelvis MRI), [ 18 F]FDG-PET/CT, and/or [ 18 F]FDG-PET/MRI in the same patients for MM initial staging. Pooled sensitivities and concordance between imaging modalities were analyzed using R (package META-R). Heterogeneity and bias were assessed with the QUADAS-C tool. RESULTS: Twenty studies (published between 2007 and 2025) using the international MM diagnostic criteria as a reference standard met the inclusion criteria. Of these, 13 (n=742) compared per-patient sensitivity of [ 18 F]FDG-PET/CT and MRI, and 4 (n=224) compared MRI and [ 18 F]FDG-PET/MRI. Pooled sensitivities were 0.807 (95% CI: 0.74-0.86) for [ 18 F]FDG-PET/CT (with significant heterogeneity) versus 0.914 (95% CI: 0.88-0.94) for MRI (0.906 for spine/pelvis MRI and 0.920 for WB-MRI) ( P <0.001 for meta-regression analysis). Using contingency tables, 83% (599/721) of included patients had concordant [ 18 F]FDG-PET/CT and MRI results, while 14% (101/721) patients had negative [ 18 F]FDG-PET/CT and positive MRI with significant differences between the 2 techniques for the paired sample analysis ( P <0.001). The pooled sensitivity of the 4 studies including [ 18 F]FDG-PET/MRI was 0.944 (95% CI: 0.88-0.98). Consensus definitions for specificity in MM imaging should be standardized across studies. CONCLUSIONS: This systematic review and comparative meta-analysis demonstrates superior sensitivity of WB-MRI compared with [ 18 F]FDG-PET/CT for initial staging of MM patients. Future international guidelines might prioritize MRI and [ 18 F]FDG-PET/MRI for staging of MM patients. REGISTRATION: PROSPERO CRD42024564937.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tordjman M, Yuce M, Geahchan A, et al. Comparison of MRI, [ 18 F]FDG-PET/CT, and [ 18 F]FDG-PET/MRI for Initial Staging of Multiple Myeloma : A Systematic Review and Meta-analysis. Clin Nucl Med. 2025. PMID: 40644586. doi:10.1097/RLU.0000000000006048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。